Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Teva Pharmaceuticals Europe
There are no treatment groups or interventions to which the patients can be randomly assigned. Data will be collected in a routine setting on a single occasion during an otherwise normal visit at the physician's office or clinic. Participating physicians will not perform any medical procedures that are outside of their normal daily clinical practice. All treatment decisions are at the sole discretion of the participating physicians and reflect their current standard of care
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patient ≥ 18 years of age who has been diagnosed with persistent asthma or patient ≥ 40 years of age and/or (ex)-smoker with more than 10 pack years of smoking who has been diagnosed with COPD
Treatment with a stable dose (no change in dose or change by less than 50% in the last 3 months) of a Inhaled corticosteroid (ICS), Long-acting beta2-agonists (LABA), Fixed dose combination (FDC) administered twice daily by Dry powder inhaler (DPI) for 3 months prior to enrollment in accordance with its approved indication
Patient is willing and able to provide written informed consent;
Patient agrees to participate in the study and to disclose any medical events to the treating physician;
Patient is able to complete the questionnaires.
You may not be if
Current enrolment or planned enrolment in an interventional study (patients are allowed to participate in other observational or case-control studies).
Clareo Health | Study in Patients' With Persistent Asthma and Chronic Obstructive Pulmonary Disease
